Bone and joint infections (BJI) with and without prosthetic material (knee, hip and shoulder) are complex to diagnose and treat, justifying the creation of expert centers by the French Ministry of Health (CRIOAc).
In case of BJI with material, the diagnosis is based on a set of clinical, bacteriological, cytological and radiological criteria known as the EBJIS 2021 (European Bone & Joint Infections Society) criteria. For septic arthritis, diagnosis is based on bacteriology and cytology.
Microbiology remains essential, and the delay of obtention of microbiological results is crucial to adapt the antibiotic treatment. Although, culture-based microbiology remains the most common diagnosis of BJI, its regular failure to identify the causative pathogen as well as its long-term modus operandi motivates the development of rapid and accurate molecular methods.
The DendrisCHIP®OA platform has demonstrated its ability to offer routine molecular identification of the current micro-organisms involved in BJI, in less than 5 hours, with the detection of mecA resistance genes on series of 16 to 64 samples . The DendrisCHIP®OA is CE-marked and has already been the subject of an initial publication evaluating its performance in a single center.
The main objective of this study is to evaluate the diagnostic performances of the DendrisCHIP®OA in detecting the pathogens recognized in its panel and the detection of the mecA gene compared with the routine microbiological techniques used in the inclusion centers participating to the study.
The study aims to include 100 patients during 6 months in five inclusion centers in the Ile de France region.

开始日期2023-12-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT05927311 / RecruitingN/AIIT

Prospective Study : Side Effects of Antibiotics in Bone and Joint Infections

Treatment for bone and joint infection (BJI) is not standardized, which allows a wide range of antibiotic therapy to potentially be given, most often in high doses over long periods of time. Patients are regularly confronted with the adverse effects of these antibiotics, which can lead to loss of adherence and treatment failure. The frequency, severity and impact on quality of life of the adverse effects of long-term antibiotics will be studied in a cohort followed for one year.

开始日期2023-08-11

申办/合作机构-

NCT05753215 / Recruiting临床2期IIT

Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: An Open-Label, Non- Inferiority, Randomized, Controlled Trial

The study design is a randomized, open-label, clinical trial of omadacycline vs Standard of Care (SOC) antibiotics for bone and join infection (BJI) treatment. Study participants will have their BJI regimen chosen by their treating physicians, (typically Infectious Diseases for hardware and prosthetic joint infections, or multidisciplinary Limb Salvage team for diabetic foot infections) prior to enrollment. Then participants will be randomized to an omadacycline-containing regimen versus the a priori chosen SOC regimen. Participants must require between 4 and 12 weeks of therapy for their BJI. The exact duration of therapy will be decided by the participants' treating physician. At 12 weeks, if the treating physician wishes to extend therapy, participants receiving omadacycline will be transitioned to other SOC antibiotics.
Once enrolled, participants will be followed via in-person clinic visits at the following intervals: weeks 0, 2, 4, 8, and 12. A final in-person visit will occur 2 weeks post-treatment completion. A phone survey will occur 3 months post-treatment completion. Participants in the SOC group will follow the same schedule.
Oral once-daily dosing options for S. aureus and Coagulase negative Staphylococcus are essentially non-existent. Thus, omadacycline possesses a novel and advantageous option for BJI treatment. Its convenient dosing regimen will almost certainly be associated with improved adherence, and higher adherence may, in turn, improve clinical outcome. Investigators hypothesize that omadacycline will be a well-tolerated and efficacious oral antibiotic for BJIs and will be associated with improved adherence compared with standard of care oral antibiotics. Investigators believe omadacycline addresses the unmet need for an oral antibiotic that is well-tolerated and efficacious for use as a prolonged therapy for BJIs. To this aim, investigators will perform a randomized, open-label clinical trial of omadacycline to SOC antibiotics for BJIs.

开始日期2023-05-09

申办/合作机构

The Lundquist Institute

[+2]

100 项与骨感染相关的临床结果

登录后查看更多信息

100 项与骨感染相关的转化医学

登录后查看更多信息

0 项与骨感染相关的专利（医药）

登录后查看更多信息

2,131

项与骨感染相关的文献（医药）

2025-02-01·Biomaterials

Programmed surface platform orchestrates anti-bacterial ability and time-sequential bone healing for implant-associated infection

Article

作者: Xi, Yue ; Wang, Ying ; Wang, Yuchen ; Tang, Like ; Chen, Yitong ; Wang, Zhaolong ; Lai, Kaichen ; Zhang, Qi ; Yang, Guoli ; Yu, Zhou ; Tian, Anrong ; Xu, Danyu ; Gao, Changyou ; Huang, Tingben ; Li, Shuangyang ; Wu, Mengjie

Implant-associated infection (IAI) has become an intractable challenge in clinic. The healing of IAI is a complex physiological process involving a series of spatiotemporal connected events. However, existing titanium-based implants in clinic suffer from poor antibacterial effect and single function. Herein, a versatile surface platform based on the presentation of sequential function is developed. Fabrication of titania nanotubes and poly-γ-glutamic acid (γ-PGA) achieves the efficient incorporation of silver ions (Ag⁺) and the pH-sensitive release in response to acidic bone infection microenvironment. The optimized PGA/Ag platform exhibits satisfactory biocompatibility and converts macrophages from pro-inflammatory M1 to pro-healing M2 phenotype during the subsequent healing stage, which creates a beneficial osteoimmune microenvironment and promotes angio/osteogenesis. Furthermore, the PGA/Ag platform mediates osteoblast/osteoclast coupling through inhibiting CCL3/CCR1 signaling. These biological effects synergistically improve osseointegration under bacterial infection in vivo, matching the healing process of IAI. Overall, the novel integrated PGA/Ag surface platform proposed in this study fulfills function cascades under pathological state and shows great potential in IAI therapy.

2025-02-01·Biomaterials

Antibiotic-eluting scaffolds with responsive dual-release kinetics facilitate bone healing and eliminate S. aureus infection

Article

作者: Brady, Robert T. ; O’ Donnell, Peter ; O’ Brien, Fergal J. ; Zeiter, Stephan ; Moriarty, T Fintan ; Ryan, Alan ; López-Noriega, Adolfo ; Moriarty, T. Fintan ; Sheehy, Eamon J. ; von Diemling, Christian ; O' Brien, Fergal J ; Brady, Robert T ; O' Donnell, Peter ; Chen, Gang ; Widaa, Amro ; Sheehy, Eamon J ; Ryan, Emily

Osteomyelitis (OM) is a progressive, inflammatory infection of bone caused predominately by Staphylococcus aureus. Herein, we engineered an antibiotic-eluting collagen-hydroxyapatite scaffold capable of eliminating infection and facilitating bone healing. An iterative freeze-drying and chemical crosslinking approach was leveraged to modify antibiotic release kinetics, resulting in a layered dual-release system whereby an initial rapid release of antibiotic to clear infection was followed by a sustained controlled release to prevent reoccurrence of infection. We observed that the presence of microbial collagenase accelerated antibiotic release from the crosslinked layer of the scaffold, indicating that the material is responsive to microbial activity. As exemplar drugs, vancomycin and gentamicin-eluting scaffolds were demonstrated to be bactericidal, and supported osteogenesis in vitro. In a pilot murine model of OM, vancomycin-eluting scaffolds were observed to reduce S. aureus infection within the tibia. Finally, in a rabbit model of chronic OM, gentamicin-eluting scaffolds both facilitated radial bone defect healing and eliminated S. aureus infection. These results show that antibiotic-eluting collagen-hydroxyapatite scaffolds are a one-stage therapy for OM, which when implanted into infected bone defects simultaneously eradicate infection and facilitate bone tissue healing.

2024-12-01·Otolaryngologic Clinics of North America

Dental Pathophysiology of Odontogenic Sinusitis

Review

作者: Alrmali, Abdusalam E ; Wang, Hom-Lay

The article explores the understudied pathophysiology of odontogenic sinusitis (ODS) development as a result of oral surgical complications such as oroantral communication (OAC) or fistula (OAF), maxillary sinus bone grafting, and dental implantation. A temporary OAC presents most often after dental extraction, especially with posterior maxillary teeth, though can happen with any oral surgical intervention. Maxillary sinus augmentation can also cause ODS, and while the pathophysiology is incompletely understood, it may be related to OAC/OAF formation or bone graft infection. Dental implants may also lead to ODS either via displacement into the sinus, partial protrusion into the sinus, or peri-implantitis.

项与骨感染相关的新闻（医药）

2024-08-20

·生物制品圈

世界亟需金葡菌疫苗，但它仍在失败的路上

2011年春天，数据监测委员会要求默克公司及其合作者停止他们正在开展的金葡菌疫苗III期临床试验——这项针对全球细菌感染主要死因而开发的候选疫苗，在26个国家的8000名患者中进行了试验，但试验效果不佳（抗体显著增高，但VE=13.8%；-52.5, 51.6%，无显著意义），无法继续进行。接下来一年的深入研究发现，在接受心胸手术的患者中测试候选疫苗，接种了候选疫苗的试验者比注射安慰剂的患者更有可能死亡。默克公司负责该疫苗研发的首席医学官福勒博士指出，许多死亡的疫苗接种者都是死于多器官系统衰竭，专家推测这种风险可能部分源于炎症反应的扩大，但仍不确定这种试验性疫苗是如何使受试者变得更加脆弱的。反复失败的金葡菌候选疫苗： 10余款候选疫苗和3款单抗前赴后继的失败当疫苗界还沉浸在默克试验带来的伤害中时，2012年辉瑞公司推出了自己的候选疫苗试验，其中包括4种不同的金葡菌抗原。基于在小鼠中获得的良好疗效数据，辉瑞首先在健康成年人中进行了试验，随后又在3000多名接受择期手术的患者中进行了2b试验。但到2018年，这款投入5亿美金的重组工艺候选疫苗希望也已破灭。血清数据显示，虽然接种疫苗的患者产生了金葡菌抗体，但疫苗组的感染率与安慰剂组相同（针对12个主要疗效终点的VE均无显著意义）。与默克公司之前的研究一样，这项2b期试验也被终止了。后来人们进行了“曲线救国”策略，输注单克隆抗体以期提供短期保护的被动免疫。但研究发现，两种正在开发中的单克隆抗体——Arsanis公司的ASN100和Aridis公司的suvratoxumab和tosatoxumab相继在中期试验中失败。事实上在过去的25年时间里，大约有14种在研金葡菌疫苗在2期或3期临床试验中失败。一个又一个疫苗开发商投入了数百万美元，开发出了一个又一个拥有高超科学依据的候选疫苗。但无论疫苗研发策略多么有前途，无论候选疫苗在临床前研究中效果多么好，最终都没有一种疫苗能成功保护人类免受金葡菌的感染。金葡菌疫苗失败原因探索：若人体预先暴露金葡菌，疫苗就会失去作用加州大学圣迭戈分校儿科传染病科主任George Liu说：默克公司试验失败后，一连串无法解释的疫苗失败成了“房间里的大象”（意思是一些非常显而易见的，可是却一直被忽略的问题）。科学家和制造商们逐渐意识到，在投入研发金葡菌疫苗之前，需要先弄清楚什么原因导致了疫苗失效。 George Liu的实验室研究表明，金葡菌疫苗并不像其他有有效疫苗那样与免疫系统相互作用。金葡菌有办法操纵免疫系统来保护自己，使宿主防御系统和传统疫苗策略失去保护作用。这就是多年来试验失败的原因，这也为可能有效的疫苗带来了希望。金葡菌是一种与人类共存的病原体，在大多数情况下不会对人类造成伤害。多达1/3的成人和50%的儿童在鼻腔中持续携带这种病菌，但都没有任何症状。然而一旦金葡菌进入血液、肺部或软组织，就会致命。医疗器械、外科手术、未愈合的伤口和注射毒品都是人们感染金葡菌的常见途径，可导致败血症、肺炎、心内膜炎和骨感染。每年造成全球100多万人死亡，美国因此的住院费用高达数十亿美元。这种微生物对抗生素的耐药性不断增加，也限制了治疗方案的选择，增加了疫苗的紧迫性。几乎所有失败的金葡菌疫苗人体试验背后都有一个成功的小鼠临床前研究，但小鼠模型与人类有本质区别——人生活在金葡菌的环境中，而实验小鼠则不是。 George Liu在小鼠接种的疫苗与默克公司试验中使用的疫苗类似，让它们预先感染金葡菌，以观察接触金葡菌是否会影响它们随后对疫苗的反应。在从未接触过金葡菌的对照组小鼠中，疫苗 “效果很好”。但在预先暴露于金葡菌的小鼠中，疫苗没有保护作用。 2022年，研究人员在Cell Host & Microbe杂志上报告了这一结果，它反映了研究人员在临床试验中看到的情况：当金葡菌预先启动了免疫系统时，疫苗就不起作用了。金葡菌疫苗无效的机制：预先暴露的金葡菌留下了错误的免疫记忆免疫系统会产生针对抗原的特异性抗体，在第一次遇到抗原后，免疫系统会产生免疫记忆。如果再次遇到病原体/抗原，这些抗体就会被迅速召回，这种免疫记忆对长期保护至关重要。对小鼠体内抗体的深入研究表明：金葡菌扰乱了它们的免疫记忆。但金葡菌已经学会了破解它：当实验室小鼠暴露于金葡菌时，病原体会留下错误的免疫反应印记。免疫系统学会了制造抗金葡菌抗体，这些抗体会迅速赶到现场，但却无法产生保护作用。通常情况下，抗体会与细菌细胞壁上的抗原结合，然后将细菌拖到巨噬细胞或中性粒细胞等免疫细胞中，在一个称为吞噬的过程中被消化和消灭。但在George Liu的研究中，接触金葡菌的小鼠产生了带有额外糖基的抗体。这些抗体仍然附着在细菌表面，但当它们到达巨噬细胞时，免疫细胞并没有消灭病原体。当研究人员移除糖基后，吞噬作用就恢复了。这种免疫操作使金葡菌得以与人类共生，也破坏了疫苗策略。当小鼠或已经接触过这种细菌的人接种疫苗后，他们的免疫系统会优先恢复原来的免疫反应，而不是根据疫苗建立新的保护性反应。去年年底George Liu发表在Cell Reports Medicine上的一项后续研究中扩大了研究范围，研究了10种金葡菌抗原，其中许多抗原在临床试验中都失败了。这些抗原包括8种能促使机体产生自身抗体的活性疫苗抗原，以及2种候选单克隆抗体：suvratoxumab和tefibazumab。与金葡菌细胞壁相关的活性疫苗抗原对之前接触过金葡菌的小鼠没有保护作用，这些疫苗抗原只是唤醒并强化了无保护性的免疫印记。单克隆抗体对暴露于金葡菌的小鼠也无效，但原因不同——它们无法与金葡菌预编程的非保护性内源抗体竞争。这些内源抗体与细菌细胞结合在一起，所以当单克隆抗体到来时，它们无处可躲。正常情况下，内源性抗体会扑上去杀死病原体，但相反内源性葡萄球菌抗体会进入病原体，并保护细菌不被治疗药物杀死。新的变通办法：优势抗原/T细胞免疫/多价/调整人群策略尽管Liu在2023年的研究中检测的大多数抗原都被金葡菌的免疫逃避技术所击败，但这项工作表明仍有乐观的余地，以排除法的形式留给了金葡菌疫苗新思路：优势抗原策略（针对α毒素、抗原表面决定簇B）、T细胞免疫策略、多价疫苗策略、调整接种人群策略（考虑暴露于金葡菌前的生命早期人群接种）。优势抗原诱导策略：其中一种活性疫苗抗原能诱导出针对金葡菌关键毒力因子α毒素的中和抗体——即使是之前接触过这种毒素的小鼠也能产生中和抗体。这种细菌毒素使细菌在宿主免疫反应中占据优势，中和它们可以给免疫系统提供更多抗感染的机会。其次，优势抗原铁调控表面决定簇B（或称IsdB）会诱发非保护性抗体，针对引起较小免疫反应但可能因免疫印记缺陷而得不到保护的亚优势抗原区的研究更为有效。 T细胞免疫策略：研究发现了T细胞对抑制金葡菌的重要性，2014年对默克公司临床试验的一部分患者进行的跟踪分析发现，死亡率与疫苗接种者血清中某些T细胞细胞因子水平低密切相关。虽然这项研究规模较小，但死亡患者似乎对接种疫苗的T细胞反应不恰当或不存在，尽管他们体内有大量抗体，全国儿童医院重症监护医师Chris Montgomery在一封电子邮件中写道。实验室的数据表明，金葡菌α毒素会损害T细胞发育，阻碍疫苗应答。T细胞功能障碍患者也更容易反复感染金葡菌，这可能表明这些免疫细胞发挥着关键的防御作用。杜克大学福勒教授说，最终未来疫苗的最佳方法可能是多价疫苗，这些疫苗将针对金葡菌生命周期不同阶段和感染阶段的毒素、T细胞和其他多种抗原的某种组合。还有一个问题是谁应该接种疫苗。疫苗研发人员一直把重点放在已被金葡菌定植并有高感染风险的患者身上。但一些专家表示，为婴儿接种疫苗是更好的策略。欧林生物的金葡菌疫苗仍在“不确定”中 2015年，欧林生物与陆军军医大学联合开发的重组金葡菌疫苗获批临床试验。2023年II期临床研究结果发表于Vaccine杂志，安全性和免疫原性良好，疫苗组抗体水平显著提高，重复了默克和辉瑞等公司的结果。 2023年末，其适用于骨科手术人群的多中心RCT 3期临床试验中期数据，向DSMB（数据监查委员会）提交审查前期临床试验结果和III期临床试验方案，以判断试验无效的可能性及是否需要终止试验，从而减少I类新药研发的风险。但DSMB给出的建议是：继续进行研究。这款“诺奖级”的新疫苗，有希望“花落”我国进度最快的欧林吗？ JAMA. Published online August 2, 2024. doi:10.1001/jama.2024.1015 欧林生物：重组金葡菌疫苗Ⅲ期临床试验已入组3,600余例，临床入组医院增加至60家以上 (baidu.com) 欧林生物重组金葡菌疫苗Ⅱ期临床试验研究论文在《疫苗》杂志发表 (cls.cn) 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗临床2期临床3期临床结果

2023-12-05

·GlobeNewswire-Health Care

Ashley Black Announces 31 Days of “My Favorite Things” Holiday Specials - up to 80% off

Ashley Black, Premium Products Built from Recycled MaterialsAshley Black, Net-Zero manufacturing by 2024Ashley Black, Female Owned Ashley Black, Female Run31 curated kits for everything from cellulite to sports recovery, to our facelift facial at up to 80% off HOUSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Ashley Black, inventor of the FasciaBlaster tools, announces 31 days of “My Favorite Things” holiday product specials. The curated series kicked off Dec-1 and will run through Dec 31, 2023. Ashley will showcase her favorite FasciaBlaster tools, how they work and holiday savings up to 80% off throughout the entire month of Dec. “I’ve curated FasciaBlaster kits, by ailment or need, so every issue from tired achy feet, to low back tension, to gorgeous smooth legs, we have something for everyone. The most important thing to me is that we are introducing self-care for regenerating tissue to new users and that’s a game changer.” Access holiday promotions at www.AshleyBlackGuru.com About Ashley Black: Ashley Black is Stevie Award winner, Woman of the Year, Lifetime Achievement in Consumer Goods, and Entrepreneur of the Year. She is the #1 best-selling author of “The Cellulite Myth” and “BE… From Passion and Purpose to Products and Prosperity.” She is best known for her invention of the therapy and beauty tool; the FasciaBlaster®. After suffering from Juvenile Rheumatoid Arthritis, a bone-eating infection, and a total hip replacement, she had no choice but to look for answers that would defy her medical prognosis of a life of pain management and debilitation. She discovered that limitations and pain in her body were due to thickening and scarring of fascia, the connective tissue that connects, penetrates, envelopes, and surrounds every human cell, like soil to plants. This contributed to the creation of a new field of science: Fasciology™. Since 1999 Ashley forged a career as a fascia authority with personal clients in pro sports and Hollywood. The results with her personal clients inspired her to invent the FasciaBlaster® tools in 2014 that have gone on to sell over $170M and amass 9M faithful fans. Her mission in life is to bring evidence-based bio-hacks for reverse aging, increase longevity, and improve health naturally to the mass market. Black owns The Fascia Advancement Academy and is certifying medical and sports professionals in the use of her tools and methodology and partnering with high-end spas and medical facilities to bring her vision to life. With an eco and socially conscious brand, founded and run by women, Ashley couldn't be more thrilled. For more information www.AshleyBlackGuru.com | About Ashley | Our ESG Principles CONTACTS: Communications Contact:Matt BirdCommPro Agency matt@commpro.com *See more sustainable fashion coverage and the original article: https://esgnews.com/ashley-black-announces-31-days-of-my-favorite-things-holiday-specials-up-to-80-off-promotion/ A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de1c593a-19eb-4594-8d3f-03e93cadec1c

2023-12-04

·生物探索

首创新型材料可减少细菌感染并加速骨骼愈合

爱尔兰皇家外科医学与健康科学学院（RCSI）和先进材料与生物工程研究中心（AMBER）的研究人员近期开发了一种新型手术植入物，有可能改变复杂骨感染的治疗方法。无需借助传统抗生素，当这种材料被植入受伤或感染的骨骼时，不仅可以加速骨骼愈合，而且能够降低感染的风险。这篇发表在《Advanced Materials》上的论文解决了骨感染（或骨髓炎）这一复杂的临床问题，仅在美国每年就影响约5000人。当骨头受到感染时，首要任务是尽快治愈。标准的临床治疗包括数周的抗生素治疗，通常需要切除感染部位的骨组织，但这种治疗方法起效缓慢。目前，大约一半的骨感染是由耐甲氧西林金黄色葡萄球菌（MRSA）引起的，而MRSA对抗生素具有抗药性，长时间的抗生素治疗会增加感染部位的耐受性，从而使情况更加难以控制。为了帮助患者更好地康复，RCSI的研究人员用与人体骨骼相似的物质创造了一种材料。这种材料具备支架状结构，这意味着当它被植入患处骨骼中时，会促进骨头再生。此外，RCSI研究人员在支架中注入了微小的铜纳米颗粒，这种纳米颗粒可以杀死引起大多数骨感染的细菌。研究人员还将一种特定的遗传分子（microRNA-138的抑制剂）整合到支架中，以刺激植入材料的部位形成新骨。在论文中，研究人员描述了临床前实验室测试验证了植入铜纳米颗粒和microRNA的支架可以在2周内刺激骨骼再生，支架还可以阻止80%的潜在有害细菌附着在该部位。他们还发现，植入物刺激了支架上细胞的良好血液供应，这对新形成骨骼的健康和活力至关重要。上图显示，AntagomiR-138激活支架已经很好地整合在骨缺损部位。B：骨，S：支架，BM：骨髓，CT：软骨，箭头表示血管，白色方块表示骨细胞。（图源：Advanced Materials 2023）“总的来说，我们将抗菌植入物和基因疗法做结合，形成了一个修复骨骼和预防感染的整体系统。”该研究的第一作者、RCSI组织工程研究小组 (TERG) 的博士后研究员Joanna Sadowska博士说道。“这是复杂骨损伤治疗向前迈出的重要一步，我们的研究可能会彻底改变未来患者的治疗次数。”RCSI生物工程和再生医学教授、论文首席研究员兼TERG负责人Fergal O'Brien教授看到了这一植入物的许多潜在优势。“这种植入物可以将抗菌治疗直接传递到受感染的骨骼，是一种有精准针对性的治疗方法。这样一来，身体的其他部位就无需长期暴露于抗生素之下，”他说。“此外，我们的植入物中含有铜颗粒，可以阻止细菌在该部位建立感染，同时刺激骨骼中的血管形成。植入物的性质还意味着，当骨头愈合时，身体可以自然分解材料，因此无需通过手术将其移除。”O'Brien教授是SFI先进材料和生物工程研究中心（AMBER）的副主任，他认为植入物是未来更精确、更有效地治疗患处骨骼的重要方法。“这是首个集成不同解决方案以促进骨骼再生并解决感染问题的植入物，这项新研究是向患者提供更快速、更有效治疗的重要一步。”O'Brien教授说。参考文献：Joanna M. Sadowska et al, A multifunctional scaffold for bone infection treatment by delivery of microRNA therapeutics combined with antimicrobial nanoparticles, Advanced Materials (2023). DOI: 10.1002/adma.202307639责编|探索君排版|探索君End往期精选围观王晓红教授团队：绘制单次冷冻囊胚移植成功的女性植入期外周血microRNA动态表达谱，开拓领域创新研究热文维生素B12在细胞重编程与组织再生中发挥关键作用！热文语言胎教是否有效？研究人员以脑电图监测揭示答案热文Let-7家族miRNA或为癌症潜在免疫治疗靶点热文一项最新发现或可用于阿尔茨海默病药物开发点击“阅读原文”，了解更多~

临床研究微生物疗法基因疗法